Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance
Authors:
- 1 October 2006
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 20 (12) , 1982-1991
Abstract
Except for gemcitabine, chemotherapeutic agents are ineffective with pancreatic adenocarcinoma because this cancer is resistant to apoptosis induction. Involvement of specific kinases in such resistance is likely. We developed a systematic strategy to screen the human kinome and select kinases whose inhibition in pancreatic cancer cells can increase 1) spontaneous apoptosis or 2) gemcitabine‐induced apoptosis. The pancreatic adenocarcinoma cell line MiaPaCa‐2 was transfected with 645 pairs of siRNAs directed to all human kinases. The same experiment was conducted in cells treated with 150 µM gemcitabine. Apoptosis was measured after 2 days and the results were normalized for cell viability. A panel of 56 kinases whose inhibition increased spontaneous apoptosis by at least 50% was established. Ten of them gave similar results on Panc1 and BxPC3 pancreatic adenocarcinoma cell lines. A panel of 83 kinases whose inhibition increased gemcitabine‐induced apoptosis by 50% or more was also established. Twelve kinases appeared in both panels. A cumulative increase in apoptosis was observed when inhibiting simultaneously several kinases. Such a systematic approach allowed characterization of all kinases involved in pancreatic cancer cell survival and resistance to gemcitabine. Inhibitors of these kinases, used alone or in combination, might improve the treatment of pancreatic adenocarcinoma. ‐Giroux, V., Iovanna, J., Dagorn, J‐C. Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance. FASEB J. 20, 1982–1991 (2006)Keywords
Funding Information
- Canceropôle PACA
This publication has 28 references indexed in Scilit:
- Antitumor Activity of Epidermal Growth Factor Receptor–Related Protein Is Mediated by Inactivation of ErbB Receptors and Nuclear Factor-κB in Pancreatic CancerCancer Research, 2006
- Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic CancerClinical Cancer Research, 2006
- Simultaneous Inhibition of EGFR, VEGFR, and Platelet-Derived Growth Factor Receptor Signaling Combined with Gemcitabine Produces Therapy of Human Pancreatic Carcinoma and Prolongs Survival in an Orthotopic Nude Mouse ModelCancer Research, 2005
- TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivoGenes & Development, 2005
- RNAi-based screening of the human kinome identifies Akt-cooperating kinases: a new approach to designing efficacious multitargeted kinase inhibitorsOncogene, 2005
- Chemotherapeutic Gemcitabine Doublets in Pancreatic CarcinomaSeminars in Oncology, 2005
- Structural Bioinformatics-Based Design of Selective, Irreversible Kinase InhibitorsScience, 2005
- Inhibition of Src Tyrosine Kinase Impairs Inherent and Acquired Gemcitabine Resistance in Human Pancreatic Adenocarcinoma CellsClinical Cancer Research, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- p21-Activated Kinase 5 (Pak5) Localizes to Mitochondria and Inhibits Apoptosis by Phosphorylating BADMolecular and Cellular Biology, 2003